

1 Systematic review of the clinical effectiveness of  
2 Tixagevimab/Cilgavimab for prophylaxis of  
3 COVID-19 in immunocompromised patients

4 Rhea Suribhatla<sup>1</sup>, Thomas Starkey<sup>2</sup>, Maria C Ionescu<sup>3</sup>, Antonio Pagliuca<sup>4</sup>, Alex Richter<sup>5</sup>, Lennard YW Lee<sup>2,6</sup>  
5  
6  
7  
8

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 **Affiliations:** 1. Oxford Medical School, University of Oxford, Oxford, UK. 2. Institute of Cancer and Genomic  
22 Sciences, University of Birmingham, Birmingham, UK. 3. United Kingdom Health Security Agency (UKHSA),  
23 London, UK. 4. King's College Hospital and King's College London, UK. 5. Institute of Immunology and  
24 Immunotherapy, University of Birmingham, Birmingham, UK. 6. Department of Oncology, University of Oxford,  
25 Oxford, OX3 7DQ, UK.

26  
27 **Corresponding Author:** Lennard YW Lee, Department of Oncology, University of Oxford, Oxford OX3 7DQ,  
28 lennard.lee@oncology.ox.ac.uk, 01865 617 331, Institute of Cancer and Genomic Sciences, University of  
29 Birmingham, Edgbaston, Birmingham B15 2TT, UK. L.lee.2@bham.ac.uk, 0121 414 3511

30  
31 **Conflicts of Interest:** The authors declare no potential conflicts of interest.

32  
33 **Running Title:** Clinical Effectiveness of Tixagevimab/Cilgavimab (Evusheld) for prophylaxis of COVID-19 in  
34 immunocompromised patients.  
35

36  
37 **Keywords:** COVID-19, SARS-CoV-2, immunocompromised, antibody, tixagevimab, cilgavimab, Evusheld,  
38 efficacy, systematic review.  
39  
40  
41

42 **Abstract**

43

44 **Background and aims**

45 Immunocompromised patients have a reduced ability to generate antibodies after COVID-19 vaccination and are  
46 at higher risk of SARS-CoV-2 infection, complications and mortality. Tixagevimab/Cilgavimab (Evusheld) is a  
47 monoclonal antibody combination which bind to the SARS-CoV-2 spike protein, preventing the virus entering  
48 human cells. The phase III PROVENT trial reported that immunocompromised patients given  
49 Tixagevimab/Cilgavimab had a significantly reduced risk of COVID-19 infection. However, PROVENT was  
50 conducted before the SARS-CoV-2 Omicron became prevalent. This systematic review provides an updated  
51 summary of real-world clinical evidence of Tixagevimab/Cilgavimab effectiveness in immunocompromised  
52 patients.

53

54 **Methods**

55 Two independent reviewers conducted PubMed and medRxiv searches for the period of 01/01/2021 to  
56 01/10/2022. Clinical studies which reported the primary outcome of breakthrough COVID-19 infections after  
57 Tixagevimab/Cilgavimab administration were included in the review. COVID-19-related hospitalisations, ITU  
58 admissions and mortality were assessed as secondary outcomes. Clinical effectiveness was determined using  
59 the case-control clinical effectiveness methodology. The GRADE tool was used to ascertain the level of certainty  
60 for the primary outcome in each study.

61

62 **Results**

63 17 clinical studies were included, comprising 24,773 immunocompromised participants of whom 10,775 received  
64 Tixagevimab/Cilgavimab. Most studies reported clinical outcomes during the SARS-CoV-2 Omicron wave. Six  
65 studies compared a Tixagevimab/Cilgavimab intervention group to a control group. Overall, the clinical  
66 effectiveness of prophylactic Tixagevimab/Cilgavimab against COVID-19 breakthrough infection, hospitalisation  
67 and ITU admission were 40.47%, 69.23% and 87.89%, respectively. For prevention of all-cause and COVID-19-  
68 specific mortality, overall clinical effectiveness was 81.29% and 86.36%, respectively.

69

70 **Conclusions**

71 There is a growing body of real-world evidence validating the original PROVENT phase III study regarding the  
72 clinical effectiveness of Tixagevimab/Cilgavimab as prophylaxis for immunocompromised patients, notably  
73 demonstrating effectiveness during the Omicron wave. This review demonstrates the clinical effectiveness of  
74 prophylactic Tixagevimab/Cilgavimab at reducing COVID-19 infection, hospitalisation, ITU admission and  
75 mortality for immunosuppressed individuals. It is important that ongoing larger-scale and better-controlled real  
76 world studies are initiated and evaluated to provide ongoing certainty of the clinical benefit of prophylactic  
77 antibody treatment for immunocompromised patients in the face of new variants.

78

79

80

81

82 **Introduction**

83  
84 Since the start of the COVID-19 pandemic in March 2020, understanding of SARS-CoV-2 infection susceptibility  
85 and treatment has increased. Vaccination has been proven to protect individuals from the more serious effects of  
86 COVID-19, however, patients with weakened immune systems are unlikely to gain the same level of protection.  
87 Findings from the NIHR OCTAVE trial have revealed that, after two COVID-19 vaccinations, approximately 11%  
88 of immunocompromised patients did not generate any anti-COVID-19 antibodies after 4 weeks<sup>1</sup>  
89

90 Patients may be immunocompromised for a number of medical reasons. This may be as a result of morbidities,  
91 such as cancer, blood cancer, solid organ and bone marrow transplant, renal disease, autoimmune disease,  
92 primary immunodeficiencies, liver disease, HIV or immune mediated inflammatory disorders, or because of  
93 treatments they are receiving immunosuppressants such as steroids, calcineurin inhibitors, disease modifying  
94 agents or chemotherapy. In the UK, there are around 500,000 immunocompromised people<sup>2</sup>. These individuals  
95 have been shown to be at significantly increased risk of COVID-19-related complications compared to the  
96 population<sup>3-5</sup>.  
97

98 Tixagevimab/Cilgavimab, also known as Evusheld or AZD7442, is a combination of the two human monoclonal  
99 antibodies tixagevimab and cilgavimab, given as separate intramuscular injections within the same session. The  
100 antibodies bind to independent segments of the SARS-CoV-2 spike protein, preventing the virus binding to the  
101 human ACE2 receptor and entering human cells<sup>6</sup>. The antibodies are modified to increase relative to other  
102 monoclonal antibodies<sup>6</sup>. A prophylactic dosage of 600mg- 300/300mg of tixagevimab/ cilgavimab is  
103 recommended<sup>7</sup>.  
104

105 The phase III PROVENT trial was the first clinical study for Tixagevimab/Cilgavimab. The trial included adults  
106 who were unlikely to develop an adequate vaccination response and/or were at increased risk of SARS-CoV-2  
107 exposure. The 3,460 patients prophylactically given Tixagevimab/Cilgavimab had a 76.6% reduced risk of  
108 COVID-19 infection after 3 months, and an 82.8% risk reduction after 6 months, compared to 1,737 control  
109 patients<sup>8</sup>. These results suggest that Tixagevimab/Cilgavimab could provide valuable protection for those most  
110 vulnerable to COVID-19. COVID-19 prophylaxis could reduce shielding restrictions for immunocompromised  
111 groups, potentially improving mental health and empowering a return to everyday life.  
112

113 In March 2022, the Europeans Medicine Agency (EMA)<sup>9</sup> and the United Kingdom Medicines and Healthcare  
114 products Regulatory Agency (MHRA) approved the use of Tixagevimab/Cilgavimab for adults who are unlikely to  
115 gain protection against Covid-19 from vaccination, or for whom vaccination is not recommended<sup>10</sup>. As of August  
116 2022, Tixagevimab/Cilgavimab is in use in over 32 different countries, including the United States, France and  
117 Canada, Malaysia and Japan<sup>11</sup>.  
118

119 However, the PROVENT study assessed Tixagevimab/Cilgavimab prior to the SARS-CoV-2 omicron variants.  
120 There is also doubt of the degree of clinical effectiveness in a real-world setting, particularly in preventing  
121 hospitalisations and deaths. Furthermore, some studies have cast doubt on the validity of prophylactic measures  
122 for immunocompromised patients<sup>12</sup>. Finally, there is a viewpoint that pandemic measures can be limited, curtailed  
123 or reallocated as a result of perceived decreased severity of the current variants<sup>13</sup>.  
124

125 This systematic review provides an up-to-date summary of the clinical evidence of the efficacy of  
126 Tixagevimab/Cilgavimab in immunocompromised patients and aims to address some of the ongoing questions  
127 regarding the use of prophylactic antibody therapies with Tixagevimab/Cilgavimab for the immunocompromised  
128 population.  
129  
130

131 **Methods**

132  
133 **Study design**

134 This was a systematic review of clinical studies in peer-reviewed journal articles and pre-print articles (Prospero  
135 registration 348513).

136  
137 **Search strategy**

138 Two independent reviewers conducted an electronic search strategy of two online databases, PubMed and  
139 medRxiv, including studies published in the period of 1<sup>st</sup> January 2021 to 1<sup>st</sup> October 2022. The initial search was  
140 performed with search terms including “Evusheld”, “tixagevimab”, “cilgavimab”, “AZD7442”, “AZD8895” and  
141 “AZD1061”. The reviewers then assessed each paper generated from the search and excluded articles firstly  
142 based on title, then abstract, then following review of the full text. References of the filtered papers were  
143 searched for additional studies. Additional studies were supplemented on the 1<sup>st</sup> of October following the same  
144 search strategy at the request senior policy makers. Any disagreements between the reviewers were resolved by  
145 consulting a separate adjudicator and a discussion between all three parties.

146  
147 **Eligibility and exclusion criteria.**

148  
149 Eligible studies had to meet the following criteria: (1) involved a clinical study- randomised controlled trials,  
150 observational studies or cohort studies, (2) prophylaxis treatment with Tixagevimab/Cilgavimab, (3) report of  
151 breakthrough SARS-CoV-2 infections. Other descriptions of clinical outcomes, including hospitalisation, ITU  
152 admission or deaths, and sera SARS-CoV-2 neutralising ability were reported as secondary outcomes.

153  
154 **Data extraction.**

155  
156 Once all papers from the search had been identified the two independent reviewers reviewed the full text of all  
157 identified papers. Descriptive data for each article were identified including; study design- date accessed, title,  
158 year of publication, author, author contact details, funding sources; methodology- study aim, design, setting, start  
159 and end date, duration of participation; population- population description, setting, total number randomised,  
160 baseline imbalances, withdrawals and exclusions, age, sex (percent female), race/ ethnicity, severity of illness,  
161 co-morbidities, sociodemographic data, reason for being high risk for COVID-19; intervention- number  
162 randomised to group, description, duration of treatment period, timing, delivery method, providers, co-  
163 interventions, economic information, resource requirements, integrity of delivery; comparator(s)- number  
164 randomised to group, description, duration of treatment period, timing, delivery method, providers, co-  
165 interventions, economic information, resource requirements, integrity of delivery; outcome measures- number of  
166 COVID-19 infections, infection complications, hospitalisations, deaths and the neutralising ability of sera against  
167 SARS-CoV-19. For each outcome, the time point and duration, analysis scale and unit, number of missing  
168 participants and why, statistical methods used, and appropriateness was noted and Information for risk of bias  
169 and GRADE assessments.

170  
171 Once all papers from the search had been identified the two independent reviewers reviewed the full text of all  
172 identified papers. Descriptive data for each article were identified including study design, methodology,  
173 population, intervention, comparator(s) and outcome measures. For each outcome, the time point and duration,  
174 analysis scale and unit, number of missing participants and why, statistical methods used, and appropriateness  
175 was noted and Information for risk of bias and GRADE assessments.

176  
177  
178 **Systematic review analysis**

179  
180 The risk of bias was conducted for each randomised controlled trial by two independent reviewers. A study is  
181 deemed at overall high risk if it is rated at high risk for any domain, at low risk if it is deemed low risk for all  
182 domains, and all other studies deemed at unclear risk. The GRADE tool was used to assess the certainty of the  
183 evidence for the primary outcome, judged against the following domains: participants follow up, imprecision,  
184 inconsistency, indirectness and publication bias<sup>14</sup>. GRADE levels were assigned as follows: (-)(-)(-)(-) = Level 0,  
185 (+)(-)(-)(-) = Level 1, (+)(+)(-)(-) = Level 2, (+)(+)(+)(-) = Level 3 and (+)(+)(+)(+) = Level 4.

186  
187 **Data analysis**

188  
189 The outcomes assessed in this study included: COVID-19 infection (confirmed through any approved method of  
190 detecting COVID-19 infection including polymerase chain reaction tests (PCR) and lateral flow tests (LFTs)),  
191 admissions to hospital, including ICU, due to COVID-19 infection, mortality due to COVID-19 infection and all-  
192 cause mortality, and participant serum SARS-CoV-2 neutralising ability.


193  
194 The clinical effectiveness of Tixagevimab/Cilgavimab was determined using the case-control clinical  
195 effectiveness methodology, similar to test-negative case control (TNCC) as previously reported for determining  
196 clinical effectiveness of SARS-CoV-2 vaccines<sup>15</sup>. Odds Ratios and 95% confidence intervals (CI) between  
197 intervention and control patient groups were calculated using a two-sided Fisher's Exact test, subtracted from 1

198 and multiplied by 100 to calculate each clinical effectiveness percentage. Aggregated clinical effectiveness  
199 percentages of multiple studies were generated where corresponding intervention and control data was  
200 available<sup>8,16-20</sup>. 95% confidence intervals for infection and case-outcome percentages were calculated using the  
201 Wilson score method without continuity correction<sup>21</sup>. Statistical analyses and data visualisation were performed  
202 within R version 4.1.2.  
203  
204

205 **Results**

206 The search strategy initially generated a total of 108 papers, 40 on medRxiv and 68 on PubMed. These were  
 207 narrowed down to 17 full text articles based on the study inclusion criteria. The overall search strategy for the  
 208 systematic review is set out in the PRISMA diagram (Figure 1). In total these seventeen studies included 24,773  
 209 immunocompromised participants, of whom 10,775 received Tixagevimab/Cilgavimab as a prophylactic antibody  
 210 therapy. It included studies from the United States, France, Israel, Belgium, Spain and the United Kingdom.

211 This review included ten retrospective cohort studies<sup>12,16-20,22-25</sup> (including two preprints<sup>16,20</sup>), six prospective,  
 212 observational cohort studies<sup>26-31</sup> (also including one preprint<sup>28</sup>) and one randomised controlled trial<sup>8</sup>. The studies  
 213 included adult patients who were immunocompromised or at high risk of COVID-19 infection. Patients were  
 214 immunocompromised as a result of having a solid organ transplant, chemotherapy, receiving  
 215 immunosuppressant drugs like steroids or anti-CD20s, or having a blood cancer. The majority of the studies  
 216 reported on clinical outcomes during the Omicron wave. The findings from the papers are summarised in Figure  
 217 2 and Tables 1-3, with full details of study characteristics in the Appendix.



218  
 219  
 220 Figure 1: Prisma flowchart showing systematic processing of articles.

221  
 222  
 223 **Study quality**

224  
 225 The GRADE tool was used to assess the certainty of the evidence for the primary outcome in each of the nine  
 226 included studies. Supplementary Table 1 provide a summary of the GRADE scores of each study, and the  
 227 reasons for each negative scoring.

228  
 229 The PROVENT study, the only included randomised controlled trial, was assessed according to the Cochrane  
 230 risk of bias assessment and deemed to have a low risk of bias (full summary in Appendix 2)<sup>8,32</sup>.

231  
 232  
 233 **Clinical effectiveness against breakthrough COVID-19 infections**

234  
 235 Tixagevimab/Cilgavimab is a combination of two human monoclonal antibodies targeted against the surface  
 spike protein of SARS-CoV-2. The antibodies have a modification to their Fc receptor to ensure a longer duration

236 of action and enable use as a prophylactic antibody therapy<sup>6</sup>. As such, the primary clinical effectiveness measure  
237 is the prevention of breakthrough COVID-19 infections. We identified 17 studies that reported on this measure.

238 The original phase 3 licensing study was the PROVENT study. This was a randomised controlled study,  
239 randomising 5197 patients between Tixagevimab/Cilgavimab or placebo. This demonstrated a relative risk  
240 reduction of 76.7% (95% confidence interval [CI], 46.0-90.0;  $p < 0.001$ ) after a median of 83 days from  
241 Tixagevimab/Cilgavimab administration (150/150mg) compared to placebo. The secondary outcome findings after  
242 a median of 196 days revealed a symptomatic COVID-19 infection risk reduction of 82.8% (CI: 65.8-91.4%)<sup>8</sup>.

243 Subsequent to the phase 3 study, sixteen real-world post-licensing studies have been performed assessing  
244 clinical effectiveness against breakthrough infections. Five were performed in reference to a control group<sup>16-20</sup>,  
245 and reported clinical outcomes from propensity-matched U.S. army veterans<sup>16</sup>, solid organ transplant  
246 recipients<sup>17</sup>, kidney transplant recipients<sup>19</sup> and from generally immunocompromised patients<sup>18,20</sup>. Four studies  
247 showed a reduction in COVID-19 infections in the Tixagevimab/Cilgavimab group compared to control groups<sup>16-</sup>  
248<sup>19</sup>. Chen et al compared the same participant population before and after Tixagevimab/Cilgavimab, finding a  
249 reduced infection rate post intervention<sup>20</sup>.

251 It is important to note that three studies<sup>8,18,19</sup> included 150mg/150mg Tixagevimab/Cilgavimab dosages, while  
252 three studies also included participants who received 300/300mg dosages<sup>16,17</sup>. Al Jurdi et al. also included a  
253 450/450mg Tixagevimab/Cilgavimab recipient<sup>17</sup>. Al Jurdi et al. found that, during a mean follow-up of 87 ±30  
254 days, the rate of COVID-19 infection breakthrough was higher amongst those who received the 150/150mg  
255 Tixagevimab/Cilgavimab dose compared to the 300/300mg dose ( $p = 0.025$ )<sup>17</sup>.

257 Of the eleven cohort studies without controls, six were prospective<sup>26-31</sup> and five were retrospective<sup>12,22-25</sup>.  
258 Infection rates between 0-19% over a 0.5-4-month period were reported in these cohort studies<sup>12,22-31</sup>. Nguyen et  
259 al. reported a low infection rate of 4.4% (49/1112) after a median follow-up of 63 days. Of the 29 cases with viral  
260 sequencing from Nguyen's paper, all the cases were found to be Omicron infections. At the time of the study, the  
261 mean weekly incidence rate in Ile-de-France was 1,669 infections in 100,000 inhabitants, whereas amongst the  
262 study population the incidence rate was 530 infections in 100,000 inhabitants<sup>27</sup>. Breakthrough infection rates  
263 reported across each study are summarised in Table 1.

265 Overall, the clinical effectiveness of COVID-19 breakthrough infections in patients who received group  
266 Tixagevimab/Cilgavimab compared to a control group was 40.47% (CI 29.82-49.67) ( $p < 0.0001$ ).

### 269 **Clinical effectiveness against COVID-19 hospitalisation**

271 Tixagevimab/Cilgavimab is believed to reduce the severe sequelae of hospitalisation in a similar fashion to  
272 coronavirus vaccines<sup>15,33</sup>. In the original PROVENT trial, one patient in the control group was hospitalised with a  
273 severe infection (needing non-invasive ventilation or high-flow oxygen) and four patients in the control group  
274 were hospitalised with a severe infection. There were no COVID-19 hospitalisations in the  
275 Tixagevimab/Cilgavimab group<sup>8</sup>.

277 Of the seventeen studies included in this review, sixteen have reported on hospitalisation of patients who  
278 received Tixagevimab/Cilgavimab. Six of these studies included corresponding controls<sup>8,16-20</sup>. All of these  
279 studies demonstrated reduced rates of hospitalisation in patients receiving Tixagevimab/Cilgavimab. The rates of  
280 hospitalisations in the ten cohort studies ranged between 0-9% over a 0.5-4-month period<sup>12,22-25,27-31</sup>.  
281 Hospitalisation rates reported across each study are summarised in Table 2.

283 Overall, the clinical effectiveness of Tixagevimab/Cilgavimab against COVID-19 hospital admissions was 69.23%  
284 (CI: 50.78-81.64) ( $p < 0.00001$ ).

286 Three papers also reported numbers of intensive care hospitalisation<sup>12,19,20</sup>, two of which were comparative  
287 studies<sup>19,20</sup>. Kaminski et al. reported a statistically significant reduced number in the Tixagevimab/Cilgavimab  
288 intervention group of 0.6% (2/333 cases) compared to 6.2% (6/97) in the control group<sup>19</sup>. Chen et al. reported a  
289 decreased rate of intensive care hospitalisations after Tixagevimab/Cilgavimab administration (0.6% before,  
290 0.0% afterwards)<sup>20</sup>. The clinical effectiveness against COVID-19 intensive care admission from these two studies  
291 was 87.89% (CI: 47.12-98.66) ( $p = 0.0008$ ).

### 294 **Clinical effectiveness in preventing COVID-19 mortality**


296 Prior to this systematic review, there was limited evidence about the clinical effectiveness of  
297 Tixagevimab/Cilgavimab in preventing COVID-19 mortality.

299 In the original PROVENT study, there were no coronavirus deaths in the patients treated with  
300 Tixagevimab/Cilgavimab, and two deaths in the control group (2/3461, 0.06%)<sup>8</sup>.

301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317

Of the real-world evaluation studies reviewed, sixteen reported on mortality in patients who received Tixagevimab/Cilgavimab, with six including controls<sup>8,16-20</sup>. Of these, in five studies, the rates of both COVID-19-specific deaths<sup>8,17,19</sup>, and all-cause mortality<sup>8,16,18</sup> were lower in the Tixagevimab/Cilgavimab-treated groups compared to controls. Chen et al. found no difference in COVID-19-related mortality before and after Tixagevimab/Cilgavimab<sup>20</sup>. In the ten cohort studies without controls, rates of COVID-19-specific deaths were very low, ranging between 0.00-0.48% over a 0.5-4-month period<sup>12,22-25,27-31</sup>. Eight of these studies reported mortality rates of 0.00%<sup>22-25,28-31</sup>. Al-Obaidi et al reported an all-cause mortality rate of 0.86% after a median of 53 days and was the only non-comparative cohort study which included all-cause mortality<sup>23</sup>. Mortality rates reported across each study are summarised in Table 3.

The overall clinical effectiveness percentages of Tixagevimab/Cilgavimab for patients in studies reporting all-cause mortality<sup>8,16,18</sup> and COVID-19-specific mortality<sup>8,17,19,20</sup> were 81.29% (66.93-90.28)  $p < 0.0001$  and 86.36% (CI: 6.21-99.70) ( $p = 0.0351$ ), respectively.



318  
319  
320

Figure 2: Box and whisker plot showing Clinical effectiveness of Tixagevimab/Cilgavimab against breakthrough coronavirus infection, hospitalisation, ITU admission, mortality and coronavirus-specific mortality<sup>8,12,16-20,22-31</sup>

Paper	Tixagevimab/Cilgavimab dosage	Infections/ no of participants % (95% CI)		Relative effect (95% CI) or significance	Time
		Intervention	Control		
Levin et al	150/150mg (100%)	8/3441, 0.23% (0.12-0.46)	17/1731, 0.98% (0.61-1.57)	RRR 76.7% (95% CI 46.0-90.0) p<0.001	Median of 83 days
		11/3441, 0.32% (0.18-0.57)	31/1731, 1.79% (1.26-2.53)	RRR 82.8% (95% CI 65.8-91.4%)	Median of 196 days
Young-Xu et al. (preprint)	150/150mg (17%), 300/300mg (83%)	<9/1733, 0.52% (0.27-0.98)	69/6354, 1.09% (0.86-1.37)	HR 0.34 (0.13-0.87) IRR 0.32 (0.24-0.44)	Over 4 months
Al Jurdi et al.	150/150mg (40.5%), 300/300mg (59.0%), 450/450mg (0.5%)	11/222, 4.95% (2.79-8.65)	32/222, 14.41% (10.40-19.64)	Log-rank p<0.001	Mean of 87 ± 30 days after Tixagevimab/Cilgavimab; mean of 82 ± 28 after control
Kertes et al.	150/150mg (100%)	29/825, 3.52% (2.46-5.00)	308/4299, 7.16% (6.43-7.97)	OR 0.51 (95% CI: 0.30-0.84) p<0.001	3 months
Kaminski et al.	150/150mg (100%)	41/333, 12.31% (9.21-16.28)	42/97, 43.30% (33.88-53.23)	HR 0.011 (95% CI 0.063-0.198) Log-rank: P <0.001	Around 4-5 months
Chen et al. Preprint	150/150mg (some), 300/300mg (some)	102/1295, 7.88% (6.53-9.47)	121/1295, 9.34% (7.88-11.05)		Between 1-7 months
Bruel et al.	Not provided	4/29, 13.79% (5.50-30.56)	No control group		23 days
Nguyen et al.	150/150mg (100%)	49/1112, 4.41% (3.35-5.78)	No control group		Median of 63 days (IQR: 49-73)
Benotmane et al.	150/150mg (100%)	7/63, 11.11% (5.49-21.20)	Infection rates not provided for control groups		Median of 29 days (IQR: 29-33)
Stuver et al.	1x150/150mg (57.7%), 2x150/150mg (32.7%), 1x300/300mg (9.6%)	2/52, 3.85% (1.06-12.98)	No control group		Median of 79 days
Benotmane et al. (2)	150/150mg (100%)	39/416, 9.38% (6.93-12.56)	No control group		30 days
Ordaya et al.	150/150mg (100%)	8/674, 1.19% (0.60-	No control group		Median of 99 days (Range: 66-

		2.32)			108)
<b>Al-Obaidi et al.</b>	300/300mg (100%)	6/98, 6.12% (2.84-12.72)	No control group		Median of 48 days (IQR: 27.5-69)
<b>Aqeel et al.</b>	300/300mg (95%), 150/150mg (5%)	4/21, 19.05% (7.67-40.00)	No control group		Mean of 98.6 ± 36.5 days
<b>Ocon et al.</b>	300/300mg (88%), 150/150mg (12%)	1/43, 2.33% (0.41-12.06)	No control group		Mean of 100 ± 33 days
<b>Calabrese et al.</b>	150/150mg (some), 300/300mg (some)	12/412, 2.91% (1.67-5.02)	No control group		Range of 13-84 days
<b>Woopen et al.</b>	2x150/150mg (100%)	0/6, 0.00% (0.00-39.03)	No control group		About 2 months

321  
322  
323

**Table 1: Primary outcome summary** <sup>8,12,16-20,22-31</sup> (RRR: relative risk ratio; HR: hazard ratio; IRR: incidence risk ratio; OR: odds ratio; IQR: interquartile range).

Paper	Hospital admission Hospitalisations/ no of participants % (95% CI)		Relative effect (95% CI) or significance	Time course
	Intervention	Control		
<b>Levin et al.</b>	0/3441, 0.00% (0.00-0.11)	3/1731, 0.17% (0.06-0.51)		Median of 83 days
	0/3441, 0.00% (0.00-0.11)	7/1731, 0.40% (0.20-0.83)		Median of 196 days
<b>Young-Xu et al. (preprint)</b>	<9/1733, 0.52% (0.27-0.98)	38/6354, 0.60% (0.44-0.82)	HR 0.13; 95%CI, 0.02-0.99 IRR: 0.10 (0.05-0.22)	Over 4 months
<b>Al Jurdi et al.</b>	1/222, 0.45% (0.08-2.51)	6/222, 2.70% (1.24-5.77)		Mean of 87 ± 30 days after Tixagevimab/Cilgavimab; mean of 82 ± 28 after control
<b>Kertes et al.</b>	1/825, 0.12% (0.02-0.68)	27/4299, 0.63% (0.43-0.91)	p=0.07	3 months
<b>Kaminski et al. Hospitalisation</b>	4/333, 1.20% (0.47-3.05)	11/97, 11.34% (6.45-19.17)	HR, 0.046; 95% CI, 0.013-0.158; P < 0.001	Around 4-5 months
<b>Kaminski et al. Intensive care</b>	2/333, 0.60% (0.16-2.16)	6/97, 6.19% (2.87-12.84)	HR, 0.045; 95% CI, 0.008-0.240; P < 0.001	Around 4.5 months
<b>Chen et al. (preprint)</b>	6/1295, 0.46% (0.21-1.01)	36/1295, 2.78% (2.01-3.82)	rate ratio (RR) = 0.20; 95% confidence	Between 1-7 months

Hospitalisation			intervals (CI) = 0.09-0.45; p <0.001	
<b>Chen et al. (preprint)</b> Intensive care	0/1295, 0.00% (0.00-0.30)	8/1295, 0.62% (0.31-1.21)		Between 1-7 months
<b>Nguyen et al.</b>	6/1112, 0.54% (0.25-1.17)	No control group		Median of 63 days (IQR: 49-73)
<b>Benotmane et al. (preprint)</b>	2/63, 3.17% (0.87-10.86)	Not provided for control group		Median of 29 days (IQR: 29-33)
<b>Stuver et al.</b>	0/52, 0.00% (0.00-6.88)	No control group		Median of 79 days
<b>Benotmane et al. (2)</b> Hospitalisation	14/416, 3.37% (2.02-5.57)	No control group		30 days
<b>Benotmane et al. (2)</b> Intensive care	3/416, 0.72% (0.25-2.10)	No control group		30 days
<b>Ordaya et al.</b>	2/674, 0.30% (0.08-1.08)	No control group		Median of 99 days (Range: 66-108)
<b>Al-Obaidi et al.</b>	42/463, 9.07% (6.78-12.03)	No control group		Median of 48 days (IQR: 27.5-69)
<b>Aqeel et al.</b>	0/21, 0.00% (0.00-15.46)	No control group		Mean of 98.6 ± 36.5 days
<b>Ocon et al.</b>	0/43, 0.00% (0.00-8.20)	No control group		Mean of 100 ± 33 days
<b>Calabrese et al.</b>	1/412, 0.24% (0.04-1.36)	No control group		Range of 13-84 days
<b>Woopen et al.</b>	0/6, 0.00% (0.00-39.03)	No control group		About 2 months

324  
325  
326

**Table 2: Secondary outcome hospitalisations summary** <sup>8,12,16-20,22-25,27-31</sup> (RRR: relative risk ratio; HR: hazard ratio; IRR: incidence risk ratio; OR: odds ratio; IQR: interquartile range)

Paper	Mortality type	Mortality Total mortality/ no of participants % (95% CI)		Relative effect (95% CI) or significance	Time course
		Intervention (95% CI)	Control		
<b>Levin et al.</b>	All-cause	9/1341, 0.67% (0.35-1.27)	7/1731, 0.40% (0.20-0.83)		Median of 196 days
		4/3461, 0.12% (0.04-0.30)	4/1736, 0.23% (0.09-0.59)		Median of 83 days
<b>Levin et al.</b>	Covid-19-related	0/3461, 0.00% (0.00-0.11)	2/3461, 0.06% (0.02-0.21)		

<b>Young-Xu et al. (preprint)</b>	All-cause	<9/1733, 0.52% (0.27-0.98)	99/6354, 1.56% (1.28-1.89)	HR 0.36; 95%CI, 0.18-0.73	Over 4 months
<b>Al Jurdi et al.</b>	Covid-19-related	0/222, 0.00% (0.00-1.70)	3/222, 1.35% (0.46-3.90)		Mean of 87 ± 30 days after Tixagevimab/Cilgavimab; mean of 82 ± 28 after control
<b>Kertes et al.</b>	All-cause	0/825, 0.00% (0.00-0.46)	40/4299, 0.93% (0.68-1.26)	p=0.005	3 months
<b>Kaminski et al.</b>	Covid-19-related	1/333, 0.30% (0.05-1.68)	2/97, 2.06% (0.57-7.21)	HR, 0.076; 95% CI, 0.005–1.161; p = 0.066	Around 4-5 months
<b>Chen et al. (preprint)</b>	Covid-19-related	0/1295, 0.00% (0.00-0.30)	0/1295, 0.00% (0.00-0.30)		Between 1-7 months
<b>Nguyen et al.</b>	Covid-19-related	2/1112, 0.18% (0.05-0.65)	No control group		Median of 63 days (IQR: 49–73)
<b>Benotmane et al. (preprint)</b>	Covid-19-related	0/63, 0.00% (0.00-5.75)	Mortality not provided for control group		Median of 29 days (IQR: 29-33)
<b>Stuver et al.</b>	Covid-19-related	0/52, 0.00% (0.00-6.88)	No control group		Median of 79 days
<b>Benotmane et al. (2)</b>	Covid-19-related	2/416, 0.48% (0.13-1.74)	No control group		30 days
<b>Ordaya et al.</b>	Covid-19-related	0/674, 0.00% (0.00-0.57)	No control group		Median of 99 days (Range: 66-108)
<b>Al-Obaidi et al.</b>	All-cause	4/463, 0.86% (0.34-2.20)	No control group		Median of 53 days (IQR 18-91)
<b>Al-Obaidi et al.</b>	Covid-19-related	0/463, 0.00% (0.00-0.82)	No control group		Median of 53 days (IQR 18-91)
<b>Aqeel et al.</b>	Covid-19-related	0/21, 0.00% (0.00-15.46)	No control group		Mean of 98.6 ± 36.5 days
<b>Ocon et al.</b>	Covid-19-related	0/43, 0.00% (0.00-8.20)	No control group		Mean of 100 ± 33 days
<b>Calabrese et al.</b>	Covid-19-related	0/412, 0.00% (0.00-0.92)	No control group		Range of 13-84 days
<b>Woopen et al.</b>	Covid-19-related	0/6, 0.00% (0.00-39.03)	No control group		About 2 months

**Table 3: Secondary outcome mortality summary** <sup>8,12,16–20,22–25,27–31</sup> (RRR: relative risk ratio; HR: hazard ratio; IRR: incidence risk ratio; OR: odds ratio; IQR: interquartile range)

327  
328  
329  
330  
331

**Neutralising ability of patient sera**

332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356

Five included studies analysed the neutralising ability of patient sera after Tixagevimab/Cilgavimab administration<sup>8,12,26,28,29</sup>. The phase III PROVENT trial showed that the neutralising antibody titres to the wild-type SARS-CoV-2 receptor-binding domain (RBD) after Tixagevimab/Cilgavimab was significantly higher than the convalescent plasma antibody titres of healthy patients from the phase I trial<sup>8</sup>.

However, analysis from different papers shows varying amounts of neutralisation of different SARS-CoV-2 variants. Bruel et al. found that, 15-30 days post Tixagevimab/Cilgavimab (dosage not provided), sera from 8 of the 11 participants had neutralising activity against Omicron variant BA.1, and all 11 were able to neutralise BA.2. Neutralisation of SARS-CoV-2 delta variant was nine-fold higher than BA.2 neutralisation in the 11 Tixagevimab/Cilgavimab-treated participants<sup>26</sup>. After a median of 33 and 29 days of 150/150mg Tixagevimab/Cilgavimab, respectively, both Stuver's and Benotmane's studies showed minimal Omicron-RBD neutralisation<sup>28,29</sup>. Stuver found that, although participant sera had high anti-spike IgG levels and effective wildtype-RBD neutralisation, the median Omicron-RBD neutralisation failed to reach the positive cut-off value<sup>29</sup>. Similarly, Benotmane found that only 9.5% of patient plasma (6/63) was able to neutralise Omicron variant BA.1 RBD, compared to 71% of patients who were infected naturally with SARS-CoV-2<sup>28</sup>. Benotmane et al. (2) also found that, of the five kidney transplant recipients with breakthrough COVID-19 infection tested, all 5 had minimal anti-RBD IgG levels against SARS-CoV-2 BA.1 (<3500BAU/mL)<sup>12</sup>.

Of note, Stuver's study showed that those who were administered two 150/150mg or a 300/300mg Tixagevimab/Cilgavimab dose had significantly higher Omicron-RBD neutralisation ( $p=0.003$ ), with 90% of patient sera neutralisation levels above the positive cut-off value<sup>29</sup>.

357 **Discussion**

358  
359 This systematic review has assessed all clinical studies reporting on the clinical effectiveness of  
360 Tixagevimab/Cilgavimab. Prophylactic therapy showed clinical effectiveness against coronavirus breakthrough  
361 infections of 40.47%, COVID-19 hospitalisation of 69.23%, ITU admission of 87.89%, all-cause mortality of  
362 81.29% and COVID-19-specific mortality of 86.36%.

363  
364 Globally, countries are still grappling with ongoing waves of COVID-19, often driven by new coronavirus variants.  
365 Population-scale coronavirus vaccination programmes have been effective in preventing the most severe  
366 sequelae in the majority of healthy individuals. However, these have not been able to completely prevent  
367 transmission amongst individuals, many of whom may have minor or asymptomatic infections<sup>34</sup>.

368  
369 It is also evident that there are groups of patients who remain at increased risk of severe outcomes, including  
370 immunocompromised individuals. While booster vaccinations have been shown to provide moderate protection  
371 for some of these patients<sup>35</sup>, many are unable to elicit appropriate immune responses following multiple  
372 coronavirus boosters. Thus, booster vaccination alone is unlikely to equitably mitigate the excess risk in these  
373 patient groups.

374  
375 The long-acting prophylactic antibody therapy Tixagevimab/Cilgavimab has been shown to be an effective  
376 measure for immunocompromised patient groups. The original licensing study, PROVENT has changed clinical  
377 practice globally, and 32 countries now use prophylactic antibody therapy in conjunction with vaccination as their  
378 pandemic standard of care<sup>36</sup>. However, some uncertainty does remain. The original PROVENT study was  
379 performed prior to the recent SARS-CoV-2 waves driven by the omicron variants. Furthermore, when new  
380 SARS-CoV-2 variants emerge, there are invariably calls for new randomised clinical trials. This systematic review  
381 is therefore important and is the first to review the existing body of evidence as to the clinical effectiveness of this  
382 treatment during the omicron era.

383  
384 This systematic review included 17 large scale human studies, including a total of 24,773 immunocompromised  
385 participants, of whom 10,775 received Tixagevimab/Cilgavimab as a prophylactic antibody therapy. While our  
386 findings are generally positive, it should be acknowledged that the real-world studies differed in quality. Many  
387 studies did not have perfect controls and comprised different patient groups. It is also the case that the studies  
388 report on current real-world effectiveness against current SARS-CoV-2 variants and cannot forecast clinical  
389 effectiveness against future SARS-CoV-2 variants.

390  
391 From a wider perspective, we must note that surrogate measures of clinical effectiveness such as laboratory  
392 neutralisation assays using synthetic or derived virus have illustrated potential resistance to  
393 Tixagevimab/Cilgavimab<sup>37,38</sup>. Indeed, antibody therapies have additional functions other than simple  
394 neutralisation, including regulation of cell-mediated cytotoxicity, agglutination and opsonisation. The results of  
395 this systematic review suggest that the higher 300mg/300mg dosage of Tixagevimab/Cilgavimab, which is  
396 recommended by the manufacturer<sup>11</sup>, could reduce the chance of SARS-CoV-2 Omicron strain resistance. We  
397 believe surrogate markers of clinical effectiveness of clinical effectiveness must be validated prior to extrapolating  
398 clinical conclusions. Indeed, two of the studies included in this paper found a high interindividual variability in  
399 neutralising antibody levels post- Tixagevimab/Cilgavimab<sup>24,28</sup>, with Aqeel et al. reporting that change in IgG  
400 levels post- Tixagevimab/Cilgavimab was only reported in one patient<sup>24</sup>.

401  
402 In summary, this systematic review has illustrated that there is now a growing body of real-world evidence  
403 validating the original phase 3 study as to the clinical effectiveness of Tixagevimab/Cilgavimab and  
404 demonstrating effectiveness in the Omicron era. It is critically important that larger-scale and better-controlled  
405 pilots and evaluations are performed to highlight the significant clinical benefit of prophylactic antibody treatment  
406 in immunocompromised groups. Further co-ordinated work is required to ensure that the risk to these vulnerable  
407 individuals from coronavirus is further mitigated and there is an ongoing pipeline of long-acting medical products  
408 which could provide even higher levels of protection as the pandemic continues.

409  
410  
411

412  
413  
414

**Supplementary Table 1: primary outcome GRADE scores** <sup>8,12,16–20,22–31</sup>

Paper	Study population	GRADE score = Level [Reason key]
Levin et al.	Adults at increased risk of SARS-CoV-2 infection	(+)(+)(+)(-) = Level 3 [a]
Young-Xu et al. (preprint)	Immuno-compromised U.S. Veterans	(+)(+)(-)(-) = Level 2 [b]
Al Jurdi et al.	Solid organ transplant recipients	(+)(+)(-)(-) = Level 2 [b]
Kertes et al.	Immunocompromised patients at Maccabi HealthCare Services, Israel	(+)(+)(-)(-) = Level 2 [b]
Kaminski et al.	Kidney transplant recipients	(+)(+)(-)(-) = Level 2 [b]
Chen et al. (preprint)	Immunocompromised patients	(+)(+)(-)(-) = Level 2 [b]
Bruel et al.	Immunocompromised individuals. 18/29 participants had previously been administered Ronapreve, a mean of 35 days before Tixagevimab/Cilgavimab administration	(+)(-)(-)(-) = Level 1 [b, c]
Nguyen et al.	Immunocompromised patients	(+)(-)(-)(-) = Level 1 [b, d]
Benotmane et al. (preprint)	Kidney transplant recipients	(-)(-)(-)(-) = Level 0 [b, c, d]
Stuver et al.	Patients with haematological malignancies	(+)(-)(-)(-) = Level 1 [b, d]
Benotmane et al. (2)	Kidney transplant recipients	(+)(-)(-)(-) = Level 1 [b, d]
Ordaya et al.	Immunocompromised patients	(+)(-)(-)(-) = Level 1 [b, d]
Al-Obaidi et al.	Immunocompromised patients	(-)(-)(-)(-) = Level 0 [a, b, d]
Aqeel et al.	Rituximab-treated antineutrophil cytoplasmic antibody vasculitis patients	(+)(-)(-)(-) = Level 1 [b, d]
Ocon et al.	Rheumatological patients on Rituximab	(+)(-)(-)(-) = Level 1 [b, d]
Calabrese et al.	Those with immune-mediated inflammatory disease, undergoing B cell depleting therapy, and those with inborn errors of humoral immunity	(+)(-)(-)(-) = Level 1 [b, d]
Woopen et al.	Multiple sclerosis patients	(-)(-)(-)(-) Level 0 [b, c, d]

415  
416  
417  
418  
419  
420  
421  
422  
423  
424

**Grade Reason Key**

- a: Risk of bias (potential missing outcome data and selection of reported results)
- b: Observational study
- c: Risk of bias (lack of matching of control and intervention groups)
- d: Risk of bias (no control group)

425 **Appendix 1**

426

427 **Risk of bias assessment: Levin et al.**<sup>8,32</sup>

428

1. Risk of bias arising from the randomization process

429

- Was the allocation sequence random? Yes, via a random number generator

430

- Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Yes

431

432

- Did baseline differences between intervention groups suggest a problem with the randomization process? No baseline differences

433

434

● **Low risk of bias**

435

436

2. Risk of bias due to deviations from the intended interventions (effect of assignment to intervention)

437

- Were participants aware of their assigned intervention during the trial? Yes, for the consideration of vaccination status

438

439

- Were carers and people delivering the interventions aware of participants assigned intervention during the trial? The pharmacists were unblinded, but the investigators and staff involved in follow-up and patient care were blinded

440

441

- Were there deviations from the intended intervention that arose because of the trial context? No, the proportion of participants who were aware of their assignments were balanced between both groups.

442

443

444

● **Low risk of bias**

445

446

3. Missing outcome data

447

- Were data for this outcome available for all, or nearly all, participants randomized? No, some data missing- out of 5,197 participants, only 4,685 were evaluated. Reasons given include loss to follow-up or discontinuation, but further information is not provided

448

449

- Is there evidence that the result was not biased by missing outcome data? Not clear

450

451

- Could missingness in the outcome depend on its true value? Unlikely

452

● **Unclear risk of bias**

453

454

4. Risk of bias in measurement of the outcome

455

- Was the method of measuring the outcome inappropriate? No

456

- Could measurement or ascertainment of the outcome have differed between intervention groups? Probably not

457

458

- Were outcome assessors aware of the intervention received by study participants? No

459

● **Low risk of bias**

460

461

5. Risk of bias in selection of the reported result

462

- Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis? Details for the primary analysis were outlined in the protocol, but this was not the case for the secondary, 6-month analysis.

463

464

- Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g., scales, definitions, time points) within the outcome domain? Unlikely

465

466

- Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible analyses of the data? No for the primary; unclear for the secondary outcomes

467

468

469

470

● **Unclear risk of bias**

471

472

473

474

475

476  
477  
478

**Appendix 2: Study characteristics**

**Levin et al. 2022<sup>8</sup>**

<p><b>Methods</b></p>	<p>Trial design: Ongoing, double-blinded, parallel-group, randomised, placebo-controlled phase 3 trial (PROVENT; NCT04625725)</p> <p>Number of participants:</p> <ul style="list-style-type: none"> <li>• Intervention: 3,460 (1,413 participants aware of randomized assignment)</li> <li>• Control: 1,737 (749 participants aware of randomized assignment)</li> <li>• (Intervention and controls were randomly assigned in a 2:1 ratio)</li> </ul> <p>Number of participants evaluated:</p> <ul style="list-style-type: none"> <li>• Intervention: 3,441</li> <li>• Control: 1,731</li> </ul> <p>Estimated trial completion date: 30 November, 2023</p>
<p><b>Population</b></p>	<p>Setting: Outpatients in Belgium, France, Spain, UK, US</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• ≥18 years at time of signing informed consent</li> <li>• increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Increased risk classification: older (≥60 years of age), obese, immunocompromised, or unable to receive vaccines without adverse effects or as having congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, or chronic liver disease</li> <li>• Medically stable</li> <li>• Negative result from point of care SARS-CoV-2 serology testing at screening</li> <li>• Contraceptive used by women of childbearing potential; condom used by men</li> <li>• Able to understand and comply with study requirements/procedures based on the assessment of the investigator</li> </ul> <p>Exclusion criteria</p> <ul style="list-style-type: none"> <li>• Significant infection or other acute illness, including fever &gt;100°F (&gt;37.8°C) on the day prior to or day of randomization.</li> <li>• History of laboratory-confirmed SARS-CoV-2 infection or any positive SARS-CoV-2 result based on available data at screening.</li> <li>• History of infection with severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).</li> <li>• Known history of allergy or reaction to any component of the study drug formulation.</li> <li>• Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mAb.</li> <li>• Any prior receipt of investigational or licensed vaccine or other mAb/biologic indicated for the prevention of SARS-CoV-2 or COVID-19 or expected receipt during the period of study follow-up.</li> <li>• Bleeding disorder or prior history of significant bleeding or bruising following IM injections or venepuncture.</li> <li>• Any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data.</li> <li>• Receipt of any IMP in the preceding 90 days or expected receipt of IMP during the period of study follow-up, or concurrent participation in another interventional study</li> <li>• Currently pregnant or breastfeeding.</li> <li>• Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 30 days prior to randomization.</li> <li>• Employees of the Sponsor involved in planning, executing, supervising, or reviewing the AZD7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.</li> <li>• In nations, states, or other jurisdictions that for legal or ethical reasons bar the enrolment of participants who lack capacity to provide their own informed consent, such subjects are excluded.</li> </ul> <p>Characteristics</p>

	<ul style="list-style-type: none"> <li>• Age (mean (±SD)) <ul style="list-style-type: none"> <li>○ Intervention: 53.6 (15.0)</li> <li>○ Control: 53.3 (14.9)</li> </ul> </li> <li>• Sex (%female) <ul style="list-style-type: none"> <li>○ Intervention: 46.1%</li> <li>○ Control: 46.2%</li> </ul> </li> <li>• Race or ethnic group <ul style="list-style-type: none"> <li>○ Intervention group: 73.6% White, 17.3% Black, 3.2% Asian, 0.5% American Indian or Alaska Native; 0.1% Native Hawaiian or as other Pacific Islander ethnic group</li> <li>○ Control group: 71.9% White, 17.4% Black, 3.5% Asian, 0.6% American Indian or Alaska Native; 0.2% Native Hawaiian or as other Pacific Islander ethnic group</li> </ul> </li> <li>• Comorbidities <ul style="list-style-type: none"> <li>○ Intervention group: 42.1% obesity; 35.5% hypertension; 20.8% smokers; 14.2% diabetes; 10.9% asthma; 7.9% cardiovascular disease; 7.2% cancer</li> <li>○ Control group: 41.0% obesity; 36.7% hypertension; 21.3% smokers; 13.9% diabetes; 11.4% asthma; 8.7% cardiovascular disease; 7.7% cancer</li> </ul> </li> <li>• Vaccination <ul style="list-style-type: none"> <li>○ Intervention: 34%</li> <li>○ Placebo: 49%</li> </ul> </li> </ul>
<b>Intervention</b>	Intervention- IM Tixagevimab/Cilgavimab (150/150mg) Control- 2x IM injections of saline placebo
<b>Outcomes</b>	<p>Primary outcomes:</p> <ul style="list-style-type: none"> <li>• Safety: The incidence of adverse events, serious adverse events, medically attended adverse events, adverse events of special interest after Tixagevimab/Cilgavimab/ placebo (Time Frame: Day 365)</li> <li>• Efficacy: The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness (Time Frame: Day 183)</li> </ul> <p>Secondary outcomes:</p> <ul style="list-style-type: none"> <li>• Investigate the efficacy of Tixagevimab/Cilgavimab compared to placebo for prevention of COVID-19 (Time Frame: 366 days)</li> <li>• Estimate the efficacy of Tixagevimab/Cilgavimab compared to placebo for prevention of severe or critical symptomatic COVID-19</li> <li>• Estimate the efficacy of Tixagevimab/Cilgavimab compared to placebo for the prevention of COVID-19-related Emergency Department visits</li> <li>• Assess the pharmacokinetics of Tixagevimab/Cilgavimab administered as a single dose of 300mg intramuscularly</li> <li>• Evaluate ADA (anti-drug antibody) response to Tixagevimab/Cilgavimab in serum</li> </ul> <p>Exploratory outcomes:</p> <ul style="list-style-type: none"> <li>• Evaluate the single dose pharmacokinetic concentrations of Tixagevimab/Cilgavimab in nasal fluid</li> <li>• Determine anti-SARS-CoV-2 nAb levels in serum following a single IM dose of Tixagevimab/Cilgavimab or placebo</li> <li>• Quantify SARS-CoV-2 viral loads in infected participants treated with a single IM dose of Tixagevimab/Cilgavimab or placebo (Illness Visits)</li> <li>• Quantify duration of viral shedding in participants with symptomatic COVID19 treated with a single IM dose of Tixagevimab/Cilgavimab or placebo (Illness Visits)</li> <li>• Characterize resistance to AZD7442 (Illness Visits)</li> <li>• Assess the biometric profiles associated with COVID-19 using a biosensor in participants treated with a single IM dose of Tixagevimab/Cilgavimab or placebo (Illness Visits)</li> <li>• Assess symptoms associated with COVID-19 using an e-Diary in participants treated with a single IM dose of Tixagevimab/Cilgavimab or placebo (Illness Visits only)</li> <li>• Assess additional immune responses following a single IM dose of Tixagevimab/Cilgavimab or placebo</li> </ul>
<b>Notes</b>	Funding: Supported by AstraZeneca and the U.S. government. AZD7442 is being developed under a contract (W911QY-21-9-0001) with the Department of Health and Human Services,

479  
480

	<p>Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, in partnership with the Department of Defense, and with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense</p> <p>Conflicts of interest:</p> <ul style="list-style-type: none"> <li>• MJL, SDW, OL: research grant or support</li> <li>• AU: advisor or review panel member</li> <li>• MS, SS, AT, YY, PA, RHA, KAN, KWD, KP, AS, KS, MNP, MTE, RAG: employee, shareholder</li> </ul>
--	--

**Young-Xu et al.**<sup>15</sup>

<b>Methods</b>	<p>Trial design: retrospective cohort study, with propensity-matched controls; preprint</p> <p>Number of participants recruited:</p> <ul style="list-style-type: none"> <li>• 1,848 patients treated with Tixagevimab/Cilgavimab (immunosuppressed or high-risk)</li> <li>• 251,756 controls (immunocompromised or high-risk patients who did not receive tixagevimab/cilgavimab)</li> </ul> <p>Number of participants included post propensity-score matching (baseline difference and immortal time bias):</p> <ul style="list-style-type: none"> <li>• 1,733 patients treated with Tixagevimab/Cilgavimab</li> <li>• 6,354 matched controls</li> </ul> <p>Completion date: follow-up period until April 30th, 2022, or until death (whichever occurred earlier). The authors generated a pseudo-tixagevimab/cilgavimab administration date for each control which followed the same distribution as the Tixagevimab/Cilgavimab administration dates.</p>
<b>Population</b>	<p>Setting: Electronic data from the U.S. Department of Veterans Affairs (VA)</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• ≥18 years (as of January 1, 2022)</li> <li>• Alive as of January 1, 2022</li> <li>• received VA healthcare until April 30, 2022, or until death</li> </ul> <p>Exclusion criteria</p> <ul style="list-style-type: none"> <li>• patients who were diagnosed with SARS-CoV-2 infection via a positive RT-PCR result or antigen testing within 3 months of the date or pseudo-date of tixagevimab/cilgavimab administration</li> </ul> <p>Characteristics</p> <p>Propensity-score matching of intervention and control cohorts was used to account for baseline group differences, and propensity-score matching survival analysis with Cox proportional hazards model was used to account for immortal time bias. Characteristics after matching:</p> <ul style="list-style-type: none"> <li>• Age (mean (±SD)) <ul style="list-style-type: none"> <li>○ Tixagevimab/Cilgavimab group: 67.4 (11.0)</li> <li>○ Controls: 68.1 (11.5)</li> </ul> </li> <li>• Sex (%male) <ul style="list-style-type: none"> <li>○ Tixagevimab/Cilgavimab group: 91%</li> <li>○ Controls: 91%</li> </ul> </li> <li>• Race or ethnic group <ul style="list-style-type: none"> <li>○ Tixagevimab/Cilgavimab group: 16% Black, 4% Hispanic, 72% non-Hispanic white, 8% Other</li> <li>○ Controls: 13% black, 4% Hispanic, 77% non-Hispanic white, 7% Other</li> </ul> </li> <li>• Most common comorbidities: <ul style="list-style-type: none"> <li>○ Tixagevimab/Cilgavimab group: 59% hypertension, 34% cancer, 31% diabetes mellitus, 23% chronic kidney disease, 69% overweight/ obese</li> <li>○ Controls: 58% hypertension, 29% cancer, 29% diabetes, 18% chronic kidney disease, 69% overweight/ obese</li> </ul> </li> <li>• Vaccination <ul style="list-style-type: none"> <li>○ Tixagevimab/Cilgavimab group: 22% 2 doses; 73% 3 doses; 5% unvaccinated</li> <li>○ Controls: 21% 2 doses; 74% 3 doses; 5% unvaccinated</li> </ul> </li> <li>• Immunocompromise state (based on ICD-10 code or use of immunosuppressive medication in preceding 30 days) <ul style="list-style-type: none"> <li>○ Tixagevimab/Cilgavimab group: 92%</li> <li>○ Controls: 92%</li> </ul> </li> </ul> <p>Difference-in-difference analysis, which adjusted for residual confounding factors using the prior event rate ratio approach was also utilised</p>
<b>Intervention</b>	<p>Intervention: at least one intramuscular dose of Tixagevimab/Cilgavimab received (in propensity-</p>

	<p>matched group: 17% 150mg/150mg; 83% 300mg/300mg Control: no Tixagevimab/Cilgavimab dose received</p>
<b>Outcomes</b>	<p>Study outcomes: SARS-CoV-2 infection, COVID-19-related hospitalization, and all-cause mortality</p> <p>Hazard Ratio calculated with propensity matching for baseline difference and immortal time bias</p> <p>Incidence rate ratio calculated with prior event rate ratio approach (difference-in-difference analysis)</p>
<b>Notes</b>	<p>Funding: Supported by the Department of Veterans Affairs (VA) Office of Research and Development, the VA Office of Rural Health, Clinical Epidemiology Program at the White River Junction VA Medical Center, by resources and the use of facilities at the White River Junction VA Medical Center and VA Informatics and Computing Infrastructure, and data from the VA COVID-19 Shared Data Resource</p> <p>Conflicts of interest: VCM has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV. YYX, GZ, CK, JS reported receiving grants from the US Food and Drug Administration through an interagency agreement with the Veterans Health Administration and from the US Department of Veterans Affairs Office of Rural Health. YYX, GZ, JS also reported receiving funding from Pfizer to US Department of Veterans Affairs for other research projects outside the submitted work. AAG received COVID-19 research project funding from the National Institutes of Health, Department of Defense, Centers for Disease Control and Prevention, AbbVie, and Faron Pharmaceuticals, outside the submitted work.</p>

481

482

Al Jurdi et al.<sup>16</sup>

<b>Methods</b>	<p>Trial design: retrospective multicenter cohort study of solid organ transplant recipients (SOTRs)</p> <p>Number of participants: Intervention group: 222 Control group: 222</p> <p>Completion date: Not provided</p>
<b>Population</b>	<p>Setting: Solid organ transplant recipients at Massachusetts General Hospital and Brigham and Women's Hospital</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Solid organ transplant recipients</li> </ul> <p>Characteristics</p> <ul style="list-style-type: none"> <li>• Age (median (IQR)) <ul style="list-style-type: none"> <li>○ Intervention group: 65 (55–72)</li> <li>○ Control group: 64 (54–70)</li> </ul> </li> <li>• Sex (% female) <ul style="list-style-type: none"> <li>○ Intervention group: 39%</li> <li>○ Control group: 41%</li> </ul> </li> <li>• Comorbidities <ul style="list-style-type: none"> <li>○ Intervention group: 7% history of SARS-CoV-2 infection; 25% coronary artery disease; 23% heart failure</li> <li>○ Control group: 19% history of SARS-CoV-2 infection; 26% coronary artery disease; 19% heart failure</li> <li>○</li> </ul> </li> <li>• Other <ul style="list-style-type: none"> <li>○ Type of transplant (%) <ul style="list-style-type: none"> <li>▪ Intervention group: 51.4% kidney; 34.7% lung; 7.7% liver; 3.2% kidney/heart; 1.8% kidney/liver; 0.9% lung/heart; 0.5% lung/kidney</li> <li>▪ Control group: 51.4% kidney; 31.5% lung; 12.2% liver; 0.5% kidney/heart; 3.2% kidney/liver; 0.5% lung/heart; 0.5% lung/kidney; 0.5% pancreas/kidney</li> </ul> </li> <li>• Years from transplantation (median (IQR)) <ul style="list-style-type: none"> <li>▪ Intervention group: 3.8 (1.9-8.2)</li> </ul> </li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>▪ Control group: 4.3 (2.7-7.0)</li> <li>• Number of vaccinations received (%): <ul style="list-style-type: none"> <li>▪ Intervention group: 0.9% none; 1.4% one; 6.8% two; 41.0% three; 47.7% four; 2.3% five</li> <li>▪ Control group: 0.0% none; 0.0% one; 9.0% two; 41.0% three; 48.2% four; 1.8% five</li> </ul> </li> <li>•</li> </ul>
<b>Intervention</b>	Intervention: Tixagevimab/Cilgavimab - 90 (40.5%) 150–150mg, 131 (59.0%) 300–300mg and one (0.5%) 450–450 mg Control: did not receive Tixagevimab/Cilgavimab
<b>Outcomes</b>	Primary: development of any breakthrough SARS-CoV-2 infection, defined as a newly positive polymerase chain reaction or antigen test, whether performed for symptoms or for another indication Additional study outcomes: outcomes included hospitalization or death from SARS-CoV-2 infection, changes in allograft function and occurrence of adverse events after receiving tixagevimab/cilgavimab
<b>Notes</b>	Funding: Supported by the Harold and Ellen Danser Endowed/Distinguished Chair in Transplantation at Massachusetts General Hospital (Boston, MA, USA). Conflicts of interest: none declared

483  
484

**Kertes et al.<sup>17</sup>**

<b>Methods</b>	Trial design: retrospective observational study Number of participants: Intervention group: 825 Control group: 4,299 Completion date: 26.05.2022
<b>Population</b>	Setting: Immunocompromised patients at Maccabi HealthCare Services, Israel. All participants invited for Tixagevimab/Cilgavimab administration by SMS/ email Inclusion criteria: <ul style="list-style-type: none"> <li>• Severe immunosuppression</li> <li>• &gt;= 12 years</li> <li>• Minimum weight of 40kg</li> </ul> Exclusion criteria <ul style="list-style-type: none"> <li>• Positive test result (PCR or antigen) in the last month</li> <li>• Vaccinated against covid-19 in last two weeks</li> </ul> Characteristics <ul style="list-style-type: none"> <li>• Age <ul style="list-style-type: none"> <li>○ Intervention group (range in years (%)): 12-39 (4.1%); 40-59 (29.9%); 60-69 (28.6%); 70-79 (30.5%); 80+ (6.8%)</li> <li>○ Control group (range in years (%)): 12-39 (13.9%); 40-59 (32.4%); 60-69 (22.6%); 70-79 (21.3%); 80+ (9.9%)</li> </ul> </li> <li>• Sex (% male): <ul style="list-style-type: none"> <li>○ Intervention group: 62.1</li> <li>○ Control group: 53.3</li> </ul> </li> <li>• Comorbidities: <ul style="list-style-type: none"> <li>○ Intervention group: 32.6% cardiovascular disease; 29.2% diabetes; 58.8% hypertension; 64.1% cancer; 61.9% chronic kidney disease; 26.1% obesity</li> <li>○ Control group: 28.1% cardiovascular disease; 25.8% diabetes; 49.4% hypertension; 65.4% cancer; 49.4% chronic kidney disease; 25.2% obesity</li> </ul> </li> <li>• Other <ul style="list-style-type: none"> <li>○ Number of COVID vaccines <ul style="list-style-type: none"> <li>▪ Intervention group: 1.2% none; 7.5% one-two; 91.3% three-four</li> <li>▪ Control group: 12.0% none; 11.7% one-two; 76.3% three-four</li> </ul> </li> <li>• Prior COVID-19 infection (%) <ul style="list-style-type: none"> <li>▪ Intervention group: 20.7%</li> <li>▪ Control group: 25.9%</li> </ul> </li> </ul> </li> </ul>

<b>Intervention</b>	Intervention: Administered Tixagevimab/Cilgavimab 150/150mg Control: Not administered Tixagevimab/Cilgavimab
<b>Outcomes</b>	Primary: SARS-CoV-2 infection, defined as any person with a recorded positive polymerase chain reaction (PCR) or positive antigen test result Additional study outcomes: severe COVID-19 disease, defined as either COVID-19-related hospitalization and/or all-cause mortality OR calculated after adjustment, but no more details provided.
<b>Notes</b>	Funding: None declared Conflicts of interest: SSBD and LA have both received funding for research from Pfizer. None of the authors have 17 received funding for any purpose from Astra Zeneca (maker/supplier of AZD7442). No other 18 conflicts of interest to report for all other authors. SSBD reports receiving payment from Pfizer 19 for a lecture. LA reports payments made to the institution from Pfizer (Grant ID 65254759) for a 20 study about Varenicline

485  
486

**Kaminski et al.**<sup>18</sup>

<b>Methods</b>	Trial design: retrospective real-life study Number of participants: Intervention: 333 Control: 97  Completion date: Last follow-up was May 5, 2022
<b>Population</b>	Setting: Bordeaux University Hospital (France) Inclusion criteria: <ul style="list-style-type: none"> <li>• Kidney transplant recipients</li> <li>• anti-spike antibody level of &lt;7 BAU/ml (threshold of detection) or between 7 and 264 BAU/ml, respectively, after at least 3 doses of mRNA vaccines</li> </ul> Exclusion criteria Characteristics <ul style="list-style-type: none"> <li>• Age (mean (±SD) years) <ul style="list-style-type: none"> <li>○ Intervention group: 60 (14.4)</li> <li>○ Control group: 58.3 (14.3)</li> </ul> </li> <li>• Sex (%) <ul style="list-style-type: none"> <li>○ Intervention group: 61.2%</li> <li>○ Control group: 64.9%</li> </ul> </li> <li>• BMI (mean (±SD) kg/m<sup>2</sup>) <ul style="list-style-type: none"> <li>○ Intervention group: 25.5 (5.3)</li> <li>○ Control group: 25.4 (5.2)</li> </ul> </li> </ul>
<b>Intervention</b>	Intervention- Intramuscular 150/150mg Tixagevimab/Cilgavimab Control- did not receive Tixagevimab/Cilgavimab
<b>Outcomes</b>	Assess the effect of Tixagevimab/Cilgavimab on COVID-19 infections and hospitalizations in kidney transplant patients
<b>Notes</b>	Funding: None declared Conflicts of interest: None declared

487  
488

**Chen et al.**<sup>18</sup>

<b>Methods</b>	Trial design: Retrospective electronic medical record study Number of participants: 1295 Intervention group: Immunocompromised patients Completion date: 31.07.2022
<b>Population</b>	Setting: University of California San Diego's Health System Inclusion criteria: <ul style="list-style-type: none"> <li>- Immunocompromised patients</li> </ul> Characteristics: <ul style="list-style-type: none"> <li>- Age (median (range)): 59 (18-99) years</li> <li>- Sex (% male): 57.5%</li> <li>- Underlying disease: 47.7% bone marrow transplant recipients/ haematologic malignancies, 37.2% solid organ transplant recipients</li> </ul>

489  
490

<b>Intervention</b>	Prophylactic intramuscular Tixagevimab/Cilgavimab (some 300/300mg; some 150/150mg)
<b>Outcomes</b>	Assess COVID-19 infection and hospitalisations before and after Tixagevimab/Cilgavimab
<b>Notes</b>	Funding: none declared Conflicts of interests: none declared

**Bruel et al.**<sup>25</sup>

<b>Methods</b>	Trial design: Data from two ongoing prospective, monocentric, longitudinal, observational cohort clinical studies (NCT04750720 and NCT04870) Number of participants: 29 Completion date: Not provided
<b>Population</b>	Setting: n=8 from Centre Hospitalier Regional of Orléans, France; n=21 from Hôpital Cochin in Paris Inclusion criteria: <ul style="list-style-type: none"> <li>• adults</li> <li>• Immunocompromised individuals</li> <li>• Vaccinated</li> </ul> Exclusion criteria: N/A Characteristics <ul style="list-style-type: none"> <li>• Age: 61 (31-92 years)</li> <li>• Sex (% female): 64%</li> <li>• Comorbidities <ul style="list-style-type: none"> <li>○ 17% obesity</li> <li>○ 62% also treated with Ronapreve</li> </ul> </li> </ul>
<b>Intervention</b>	Group 1: before Tixagevimab/Cilgavimab administration Group 2: same patients, after Tixagevimab/Cilgavimab administration (dose not provided)
<b>Outcomes</b>	<ul style="list-style-type: none"> <li>• Assessed sensitivity of SARS-CoV-2 variant BA.2 to a panel of nine mAbs currently in clinical use</li> <li>• Assess differences in antibody levels and neutralization activity of sera before and after Tixagevimab/Cilgavimab</li> </ul>
<b>Notes</b>	Funding: UZ Leuven, as national reference center for respiratory pathogens, is supported by Sciensano, which is gratefully acknowledged. Work in the O.S. lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito and IDISCOVER. Work in the UPBI facility is funded by grant ANR-10-INSB-04-01 and the Région Île-de-France program DIM1Health. D.P. is supported by the Vaccine Research Institute. G.B. acknowledges support from the Internal Funds KU Leuven under grant agreement C14/18/094 and the Research Foundation–Flanders (Fonds voor Wetenschappelijk Onderzoek–Vlaanderen, G0E1420N and G098321N). P.M. acknowledges support from a COVID-19 research grant of 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders (grant G0H4420N). P.M. acknowledges support of a COVID-19 research grant from 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders (grant G0H4420N) and 'Internal Funds KU Leuven' (grant 3M170314). E.S.L. acknowledges funding from the INCEPTION program (Investissements d'Avenir grant ANR-16-CONV-0005). The funders of this study had no role in study design, data collection, analysis and interpretation or writing of the article.

491  
492

**Nguyen et al.**<sup>26</sup>

<b>Methods</b>	Trial design: prospective, observational multicentre cohort study Number of participants: 1112  Completion date: March 31st, 2022
<b>Population</b>	Setting: nine departments on three University Hospitals located in Ile-de-France (Nephrology, Haematology, Internal Medicine, Pulmonology, Rheumatology, and Cardiac Surgery) Inclusion criteria: <ul style="list-style-type: none"> <li>• Immunocompromised patients</li> </ul>

	<ul style="list-style-type: none"> <li>impaired response, defined by anti-Spike IgG antibodies &lt;264 binding antibody units per millilitre [10], after at least three doses of vaccine</li> </ul> <p>Exclusion criteria</p> <ul style="list-style-type: none"> <li>Patients with confirmed SARS-CoV-2 infection &lt;5 days following tixagevimab/cilgavimab administration</li> </ul> <p>Characteristics</p> <ul style="list-style-type: none"> <li>Age: 62 (35-89)</li> <li>Previous SARS-CoV-2 infection: 9.6%</li> </ul>
<b>Intervention</b>	Intramuscular 150/150mg Tixagevimab/Cilgavimab
<b>Outcomes</b>	Describe the incidence and the outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis, during the Omicron wave in France
<b>Notes</b>	Funding: none declared Conflicts of interest: None reported

493  
494

**Benotmane et al. (preprint)<sup>27</sup>**

<b>Methods</b>	<p>Trial design: prospective cohort study; preprint</p> <p>Number of participants:</p> <p>Intervention group: 63</p> <p>Negative control (Ronapreve): 39</p> <p>Positive control (natural infection): 14</p> <p>Completion date: not provided; but follow-up after median interval of 29 days (IQR 29-33)</p>
<b>Population</b>	<p>Setting: Kidney transplant recipients at Lyon and Strasbourg University Hospitals</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>Adult kidney transplant recipients</li> </ul> <p>Exclusion criteria</p> <ul style="list-style-type: none"> <li>Those with history of Covid-19 infection</li> <li>Those with positive anti-nucleocapsid IgG</li> </ul> <p>Characteristics not provided</p>
<b>Intervention</b>	<p>Intervention group: adult kidney transplant recipients who received prophylactic intramuscular injections of Tixagevimab/Cilgavimab (150/150mg)</p> <p>Negative controls: adult kidney transplant recipients who received prophylactic Ronapreve (casirivimab-imdevimab 600/600mg)</p> <p>Positive controls: Adult kidney transplant recipients who were infected with SARS-CoV-2 during the fifth wave of the pandemic</p>
<b>Outcomes</b>	<p>Anti-RBD IgG titers and neutralizing antibody titers against the omicron BA.1 variant were measured in serum samples</p> <p>Additional study outcomes</p>
<b>Notes</b>	<p>Funding: no funding</p> <p>Conflicts of interest: Sophie Caillard and Olivier Thaumat have received consultancy fees from Astra Zeneca. The other authors have no conflicts of interest to declare.</p>

495  
496

**Stuver et al.<sup>28</sup>**

<b>Methods</b>	<p>Trial design: prospective observational study</p> <p>Number of participants: 52</p> <p>Completion date: not provided</p>
<b>Population</b>	<p>Setting: Patients treated at Memorial Sloan Kettering Cancer Center (MSKCC)</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>Patients with haematological malignancies</li> <li>vaccinated</li> </ul> <p>Exclusion criteria</p> <p>Characteristics</p>

	<ul style="list-style-type: none"> <li>• Age: 62 (35-89)</li> <li>• Previous SARS-CoV-2 infection: 9.6%</li> </ul>
<b>Intervention</b>	Intervention- 57.7% one 150mg dose; 32.7% 2x150mg; 9.6% 1 x 300mg dose (intramuscular) Measurements taken before and after Tixagevimab/Cilgavimab administration
<b>Outcomes</b>	<ul style="list-style-type: none"> <li>• Assessment of Anti-SARS-CoV-2 spike protein (S) IgG antibody levels before and after Tixagevimab/Cilgavimab administration</li> <li>• Assessment of virus neutralisation</li> </ul>
<b>Notes</b>	Funding: none declared Conflicts of interest: None declared

497  
498

**Benotmane et al. (2)**<sup>12</sup>

<b>Methods</b>	Trial design: retrospective cohort study; preprint Number of participants: Intervention group: 416 (25 of these patients had also been treated with casirivimab-imdevimab) Completion date: 13.03.2022
<b>Population</b>	Setting: Kidney transplant recipients at Lyon and Strasbourg University Hospitals Inclusion criteria: <ul style="list-style-type: none"> <li>• Adult kidney transplant recipients</li> <li>• showed a weak serological response to SARS-CoV-2 mRNA vaccines- below 264 BAU/ml</li> </ul> Exclusion criteria <ul style="list-style-type: none"> <li>• Those with history of Covid-19 infection</li> <li>• Those with positive anti-nucleocapsid IgG</li> </ul> Characteristics of whole participant group not provided
<b>Intervention</b>	Prophylactic intramuscular injections of Tixagevimab/Cilgavimab (150/150mg)
<b>Outcomes</b>	Number of infections, hospitalisations, intensive care admissions and mortality. Viral neutralising activity of participant serum against Omicron BA.1 variant.
<b>Notes</b>	Funding: none declared Conflicts of interest: None declared

499  
500

**Ordaya et al.**<sup>21</sup>

<b>Methods</b>	Trial design: Retrospective descriptive analysis Number of participants: 674 Intervention group: Participants with severe immunocompromising conditions Completion date: Not provided
<b>Population</b>	Setting: Mayo Clinic, Rochester, Minnesota Inclusion criteria: <ul style="list-style-type: none"> <li>• 18 years or older</li> <li>• Severe immunocompromising condition</li> </ul> Characteristics of whole participant group not provided
<b>Intervention</b>	Prophylactic intramuscular injections of Tixagevimab/Cilgavimab (150/150mg)
<b>Outcomes</b>	Report of the clinical characteristics of COVID-19 infections post tixagevimab-cilgavimab. Genomic analysis to characterise specific variants of concern was also performed
<b>Notes</b>	Funding: This work was supported by an intramural grant to R. R. R. from the Mayo Clinic. P. V. was supported by the Mayo Clinic Department of Medicine Catalyst Award for Advancing in Academics. Conflicts of interest: R. R. R. has received grants from Regeneron, Roche, and Gilead for

	research not directly related to this study (research funds given to Mayo Clinic). P. V. has received research grants from Scynexis and Cidara and has served on the data and safety monitoring board for AbbVie, Vanda, and Algenron Pharmaceuticals (all fees paid to Mayo Clinic). All other authors report no potential conflicts.
--	--

501  
502

**Al-Obaidi et al.**<sup>22</sup>

<b>Methods</b>	Trial design: Retrospective chart review Number of participants: 463 Intervention group: Immunocompromised patients  Completion date: 24.05.2022
<b>Population</b>	Setting: University of Arizona, Banner University Medical Center in Tucson, Arizona Inclusion criteria: <ul style="list-style-type: none"> <li>• Moderately to severely immunocompromised</li> <li>• At least one dose of COVID-19 vaccine/ unable to receive vaccine due to severe reaction</li> </ul> Exclusion criteria: <ul style="list-style-type: none"> <li>• Recent exposure or an acute COVID-19 infection</li> </ul> Characteristics: <ul style="list-style-type: none"> <li>• Age: median 68</li> <li>• Sex (% male): 51</li> <li>• Race or ethnic group: 9% White, 13.2% Hispanic, 1.7% Black/African American, and 5.8% identified as Other</li> <li>• Underlying disease: 62.4% haematologic malignancies, 18.4% transplant, 8.6% autoimmune disease, 4.1% advanced HV, 4.1% chemotherapy</li> </ul>
<b>Intervention</b>	Prophylactic intramuscular Tixagevimab/Cilgavimab (300/300mg- either one 300/300mg, or two 150/150mg)
<b>Outcomes</b>	Report on patient underlying comorbidities, post Tixagevimab/Cilgavimab breakthrough COVID-19 infection, hospitalisation and death
<b>Notes</b>	Funding: none declared Conflicts of interests: none declared

503  
504

**Aqeel et al.**<sup>23</sup>

<b>Methods</b>	Trial design: Retrospective review Number of participants: 21 Intervention group: Rituximab-treated antineutrophil cytoplasmic antibody vasculitis patients  Completion date: June 2022
<b>Population</b>	Setting: John Hopkins University School of Medicine, Baltimore, Maryland, USA Inclusion criteria: <ul style="list-style-type: none"> <li>• Antineutrophil cytoplasmic antibody vasculitis</li> <li>• Treated with rituximab</li> </ul> Characteristics: <ul style="list-style-type: none"> <li>• Age (mean ± SD): 66 ± 15.5 years</li> <li>• Vaccination: 100% vaccinated; 95% received booster</li> </ul>
<b>Intervention</b>	Prophylactic Tixagevimab/Cilgavimab (95% 300/300mg; 5% 150/150mg; intramuscular)
<b>Outcomes</b>	Report experiences of Rituximab-treated antineutrophil cytoplasmic antibody vasculitis patients treated with Tixagevimab/Cilgavimab
<b>Notes</b>	Funding: none declared Conflicts of interests: none declared

505  
506

**Ocon et al.**<sup>29</sup>

<b>Methods</b>	Trial design: Prospective cohort study Number of participants: 43 Intervention group: Systemic autoimmune rheumatic disease patients on rituximab therapy Completion date: Not provided
<b>Population</b>	Setting: Department of Allergy, Immunology, and Rheumatology, Rochester Regional Health, Rochester, New York Inclusion criteria: <ul style="list-style-type: none"> <li>• Systemic autoimmune rheumatic disease</li> <li>• 18 years and older</li> <li>• Treated with rituximab within past 1 year</li> </ul> Characteristics: <ul style="list-style-type: none"> <li>• Age (mean ± SD): 59 ± 15 years</li> <li>• Sex (% female): 69.8%</li> <li>• Underlying disease: 48.8% rheumatoid arthritis, 30.2% ANCA vasculitis, 9.3% other vasculitis, 4.7% immune-mediated myositis, 4.7% Sjogren disease, 2.3% systemic lupus erythematosus</li> <li>• Vaccination: 81.4% 3 doses of mRNA SARS-CoV-2 vaccination; 11.6% 2 doses; 7% 1 dose</li> </ul>
<b>Intervention</b>	Prophylactic intramuscular Tixagevimab/Cilgavimab (88% 300/300mg; 12% 150/150mg)
<b>Outcomes</b>	Longitudinally follow the real-world effectiveness of Tixagevimab/Cilgavimab at preventing SARS-CoV-2 infection in systemic autoimmune rheumatic disease patients treated with rituximab
<b>Notes</b>	Funding: none declared Conflicts of interests: S.S.M. was part of the speaker's bureau for Genentech, GSK, AstraZeneca, CLS, Behring, and Regeneron.

507  
508

**Calabrese et al.**<sup>24</sup>

<b>Methods</b>	Trial design: Electronic retrospective review Number of participants: 412 Intervention group: High risk patients, including those on B cell depleting therapies and with inborn errors of humoral immunity  Completion date: 28.05.2022
<b>Population</b>	Setting: Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA Inclusion criteria: <ul style="list-style-type: none"> <li>• Patients on B cell depleting therapies</li> <li>• Patients with inborn errors of humoral immunity</li> </ul> Exclusion criteria: <ul style="list-style-type: none"> <li>• Patients receiving B cell depleting therapies for cancer</li> </ul> Characteristics: <ul style="list-style-type: none"> <li>• Underlying disease category: 62% rheumatology, 19% allergy/ immunology, 19% neurology</li> </ul>
<b>Intervention</b>	Prophylactic intramuscular Tixagevimab/Cilgavimab (some 150/150mg; some 300/300mg)
<b>Outcomes</b>	Report on real-world experience with breakthrough COVID-19 infections after Tixagevimab/Cilgavimab
<b>Notes</b>	Funding: none declared Conflicts of interests: none declared

509  
510

**Wopen et al.**<sup>30</sup>

<b>Methods</b>	Trial design: Prospective case series Number of participants: 6 Intervention group: multiple sclerosis patients under immunomodulatory treatment
----------------	--

	Completion date: 02.06.2022
<b>Population</b>	<p>Setting: Multiple Sclerosis Centre, Dresden, Germany</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Multiple sclerosis patients</li> <li>• Immunomodulatory treatment</li> <li>• Lacked antibody and T cell responses to three SARS-CoV-2 vaccinations</li> </ul> <p>Characteristics:</p> <ul style="list-style-type: none"> <li>• Age (mean): 56.7 years</li> <li>• Sex (% male): 66.7%</li> <li>• Mul</li> </ul>
<b>Intervention</b>	Intervention group: Following initial treatment with casirivimab/imdevimab and sotrovimab, participants received prophylactic intramuscular Tixagevimab/Cilgavimab (two 150/150mg)
<b>Outcomes</b>	Study outcome: Report on patient experiences post Tixagevimab/Cilgavimab
<b>Notes</b>	<p>Funding: none declared</p> <p>Conflicts of interests: none declared</p>

512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578

## References

1. Kearns, P. *et al.* Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity-the OCTAVE Trial. <https://ssrn.com/abstract=3910058>.
2. Why the Government should postpone lifting restrictions on June 21 | Blood Cancer UK. <https://bloodcancer.org.uk/news/were-calling-on-the-government-to-postpone-lifting-restrictions-on-june-21/> (2021).
3. Thorpe, M. *et al.* Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. doi:10.1101/2022.08.08.22278576.
4. 2022.08.13.22278733v1.full.
5. OpenSAFELY Collaborative, T. *et al.* Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England. doi:10.1101/2022.07.30.22278161.
6. Medical Association, A. *Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19.* <https://bit.ly/3IWpQjg> (2022).
7. Update to Evusheld recommended dosage regimen for pre-exposure prophylaxis of COVID-19. <https://www.astrazeneca.com/media-centre/statements/2022/update-to-evusheld-recommended-dosage-regimen-for-pre-exposure-prophylaxis-of-covid-19.html#!> (2022).
8. Levin, M. J. *et al.* Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. *New England Journal of Medicine* **386**, 2188–2200 (2022).
9. EMA recommends authorisation of COVID-19 medicine Evusheld . <https://www.ema.europa.eu/en/news/ema-recommends-authorisation-covid-19-medicine-evusheld> (2022).
10. Evusheld approved to prevent COVID-19 in people whose immune response is poor - GOV.UK. <https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor> (2022).
11. Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan. <https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-for-covid-19-in-japan.html>.
12. Benotmane, I. *et al.* Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. *American Journal of Transplantation* **00**, 1–7 (2022).
13. Coronavirus (COVID-19) latest insights: Lifestyle. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/lifestyle> (2022).
14. Siemieniuk, R. & Guyatt, G. What is GRADE? | BMJ Best Practice. <https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/>.
15. Lopez Bernal, J. *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* **385**, 585–594 (2021).
16. Young-Xu, Y. *et al.* Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data. doi:10.1101/2022.05.28.22275716.
17. al Jurdi, A. *et al.* Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. (2022) doi:10.1111/ajt.17128.
18. Kertes, J. *et al.* Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality. doi:10.1093/cid/ciac625.
19. Kaminski, H. *et al.* COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders. *Kidney Int* (2022) doi:10.1016/j.kint.2022.07.008.
20. Chen, B. *et al.* Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron Era.
21. Newcombe, R. G. TWO-SIDED CONFIDENCE INTERVALS FOR THE SINGLE PROPORTION: COMPARISON OF SEVEN METHODS. *STATISTICS IN MEDICINE Statist. Med* **17**, 857–872 (1998).
22. Ordaya, E. E., Beam, E., Yao, J. D., Razonable, R. R. & Vergidis, P. Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis. *Open Forum Infect Dis* **9**, (2022).
23. Al-Obaidi, M. M. *et al.* The prevention of COVID-19 in high-risk patients using tixagevimab-cilgavimab (Evusheld): Real-world experience at a large academic center. *Am J Med* (2022) doi:10.1016/J.AMJMED.2022.08.019.
24. Aqeel, F. & Geetha, D. Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients. *Kidney Int Rep* (2022) doi:10.1016/J.EKIR.2022.08.019.
25. Calabrese, C. *et al.* Letter: Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. *RMD Open* **8**, 2557 (2022).
26. Bruel, T. *et al.* Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. *Nat Med* **28**, 1297–1302 (2022).

- 579 27. Nguyen, Y. *et al.* Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19  
580 among 1112 severely immunocompromised patients. (2022) doi:10.1016/j.cmi.2022.07.015.  
581 28. Benotmane, I. *et al.* Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against  
582 the omicron variant in kidney transplant patients. doi:10.1101/2022.03.21.22272669.  
583 29. Stuver, R. *et al.* Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients  
584 with hematologic malignancies. *Cancer Cell* **40**, 590–591 (2022).  
585 30. Ocon, A. J. & Shahzad Mustafa, S. Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in  
586 Rheumatologic Patients on Rituximab. (2022) doi:10.1097/RHU.0000000000001907.  
587 31. Woopen, C., Konofalska, U., Akgün, K. & Ziemssen, T. Case report: Variant-specific pre-exposure  
588 prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses. *Front*  
589 *Immunol* **13**, (2022).  
590 32. Hirsch, C. *et al.* SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. *Cochrane*  
591 *Database of Systematic Reviews* **2022**, (2022).  
592 33. W Lee, L. Y. *et al.* Vaccine effectiveness against COVID-19 breakthrough infections in patients with  
593 cancer (UKCCEP): a population-based test-negative case-control study. *Lancet Oncology* **23**, 748–757  
594 (2022).  
595 34. Franco-Paredes, C. Transmissibility of SARS-CoV-2 among fully vaccinated individuals. *Lancet Infect Dis*  
596 **22**, 16 (2022).  
597 35. Lee, L. Y. W. *et al.* COVID-19: Third dose booster vaccine effectiveness against breakthrough  
598 coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. *Eur J*  
599 *Cancer* **175**, 1–10 (2022).  
600 36. Mahase, E. Covid-19: UK will not buy Evusheld owing to 'insufficient data' on protection, government  
601 says. *The BMJ* (2022) doi:10.1136/BMJ.O2021.  
602 37. Cameroni, E. *et al.* Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.  
603 *Nature* **2021 602:7898 602**, 664–670 (2021).  
604 38. Cao, Y. *et al.* Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* **2021**  
605 **602:7898 602**, 657–663 (2021).  
606